188 related articles for article (PubMed ID: 18079112)
1. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
Giorgini F; Möller T; Kwan W; Zwilling D; Wacker JL; Hong S; Tsai LC; Cheah CS; Schwarcz R; Guidetti P; Muchowski PJ
J Biol Chem; 2008 Mar; 283(12):7390-400. PubMed ID: 18079112
[TBL] [Abstract][Full Text] [Related]
2. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.
Giorgini F; Guidetti P; Nguyen Q; Bennett SC; Muchowski PJ
Nat Genet; 2005 May; 37(5):526-31. PubMed ID: 15806102
[TBL] [Abstract][Full Text] [Related]
3. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.
Crotti A; Benner C; Kerman BE; Gosselin D; Lagier-Tourenne C; Zuccato C; Cattaneo E; Gage FH; Cleveland DW; Glass CK
Nat Neurosci; 2014 Apr; 17(4):513-21. PubMed ID: 24584051
[TBL] [Abstract][Full Text] [Related]
4. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
Guidetti P; Reddy PH; Tagle DA; Schwarcz R
Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
[TBL] [Abstract][Full Text] [Related]
5. Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons.
Kraft AD; Kaltenbach LS; Lo DC; Harry GJ
Neurobiol Aging; 2012 Mar; 33(3):621.e17-33. PubMed ID: 21482444
[TBL] [Abstract][Full Text] [Related]
6. Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity.
Tauber E; Miller-Fleming L; Mason RP; Kwan W; Clapp J; Butler NJ; Outeiro TF; Muchowski PJ; Giorgini F
J Biol Chem; 2011 Jan; 286(1):410-9. PubMed ID: 21044956
[TBL] [Abstract][Full Text] [Related]
7. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
8. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein.
Hoshino M; Tagawa K; Okuda T; Murata M; Oyanagi K; Arai N; Mizutani T; Kanazawa I; Wanker EE; Okazawa H
J Neurochem; 2003 Oct; 87(1):257-67. PubMed ID: 12969272
[TBL] [Abstract][Full Text] [Related]
10. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Donley DW; Realing M; Gigley JP; Fox JH
PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
[TBL] [Abstract][Full Text] [Related]
11. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
12. Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.
Joyner PM; Matheke RM; Smith LM; Cichewicz RH
J Proteome Res; 2010 Jan; 9(1):404-12. PubMed ID: 19908918
[TBL] [Abstract][Full Text] [Related]
13. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
Ermak G; Hench KJ; Chang KT; Sachdev S; Davies KJ
J Biol Chem; 2009 May; 284(18):11845-53. PubMed ID: 19270310
[TBL] [Abstract][Full Text] [Related]
14. Interaction of Huntington disease protein with transcriptional activator Sp1.
Li SH; Cheng AL; Zhou H; Lam S; Rao M; Li H; Li XJ
Mol Cell Biol; 2002 Mar; 22(5):1277-87. PubMed ID: 11839795
[TBL] [Abstract][Full Text] [Related]
15. Mutant huntingtin impairs immune cell migration in Huntington disease.
Kwan W; Träger U; Davalos D; Chou A; Bouchard J; Andre R; Miller A; Weiss A; Giorgini F; Cheah C; Möller T; Stella N; Akassoglou K; Tabrizi SJ; Muchowski PJ
J Clin Invest; 2012 Dec; 122(12):4737-47. PubMed ID: 23160193
[TBL] [Abstract][Full Text] [Related]
16. Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Sti1 in spatial quality control of amyloid-like proteins.
Wolfe KJ; Ren HY; Trepte P; Cyr DM
PLoS One; 2014; 9(5):e95914. PubMed ID: 24828240
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
20. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation.
Igarashi S; Morita H; Bennett KM; Tanaka Y; Engelender S; Peters MF; Cooper JK; Wood JD; Sawa A; Ross CA
Neuroreport; 2003 Mar; 14(4):565-8. PubMed ID: 12657886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
